Q&A: Investor Outlook for 2024 (30 January)
KPMG High Growth VenturesTime & Location
Tuesday 30 January, 12:00PM - 1:00PM AEDT (Online).
Who should attend?
Blah blah blah
Event description
The last 12 months have been tumultuous to say the least: a slowdown in funding, increase due diligence, a focus on growth…and the list goes on. But now that the dust has settled, investors are starting to invest again – or so they say. Join us for this Q&A where we speak to VCs to get their take on what the next 12 months hold for the startup ecosystem.
Our PANELLISTS
- Leigh Jasper, Co-CEO of Firmable. Leigh co-founded Aconex, the world’s most widely used cloud collaboration platform for managing construction projects. As CEO, he led the company from founding, through multiple capital raisings, to an Initial Public Offering (IPO) and company sale to Oracle Ltd for $1.6 billion in 2018. Leigh grew Aconex to over $200 million in revenue, employing 850 staff across operations in 50 cities around the world, in Australia, Asia, the Middle East, Europe, South America and North America. Leigh worked in the Melbourne, San Francisco and Paris offices of Aconex. Prior to founding Aconex, Leigh worked in management consulting with McKinsey and Company. Leigh is the Chair of LaunchVic and Second Quarter Ventures and Co-Founder/CEO of Firmable, Director at SEEK Ltd, Buildxact and Payapps.
- Rachael Neumann, Founding Partner of Flying Fox Ventures. Rachael is the Founding Partner at Flying Fox Ventures, an early-stage venture capital firm propelling Australian & New Zealand companies across the globe. Over her career, Rachael has worked with thousands of early-stage startups around the globe as Head of Startups for Amazon Web Services ANZ, a Partner at Startmate, and in her two Federal Government appointments distributing commercialization and scale funding to early-stage Australian companies.
- Luis Malaver-Ortega, Founder of Me&. Dr. Luis Malaver-Ortega is the co-founder and co-CEO of Me&, bringing a wealth of expertise as a cell and molecular biologist with over 18 years of experience in the biotech field. After several appointments at CSIRO, the Australian Institute for Bioengineering and Nanotechnology (AIBN), The Monash Institute of Pharmaceutical Sciences (MIPS), The Hudson Institute of Medical Research; he is currently serving as honorary Research Fellow at the Department of molecular and translational science in Monash while he directs the R&D pipelines for the company.
Register now
Registrations are now closed.